Odevixibat pregnancy and breastfeeding safety study
Part of Women’s health & pregnancy clinical trials.
This study tracks the safety of odevixibat (a liver medicine) in women who took it during pregnancy or while breastfeeding. It helps patients and doctors understand if the medicine poses any risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took at least one dose of odevixibat while pregnant (any time from before conception to birth).
- Or you took odevixibat while breastfeeding (up to 12 months of baby's age or until weaning).
- You agree to have your information shared with the study team for safety tracking.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of a medicine called elafibranor when taken before or during pregnancy. Researchers want to understand how the medicine affects pregnant people and their babies to help keep both safe.
This is an observational study that collects real-world information about pregnancy outcomes when relugolix-containing therapy is taken during pregnancy. It aims to better understand safety for both the parent during pregnancy and the child after birth.
This study measures how much epilepsy medicine (lamotrigine, levetiracetam, or oxcarbazepine) your body absorbs during pregnancy and breastfeeding. It may help doctors better understand dosing and safety during these times.
This study follows people with Friedreich's ataxia who took omaveloxolone during pregnancy or while breastfeeding, to check how the drug affected their health and their baby's health. It helps doctors understand the safety of this treatment for mothers and babies.
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
Hear when a new Pregnancy Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.